title: Effectiveness of palosuran in bleomycin-induced experimental scleroderma.
abstract: Systemic sclerosis (SSc) is a disease characterized by skin and internal organ involvement. There is progressive accumulation of extracellular matrix components in the skin and involved organs. Tissue fibrosis is the prominent reason for mortality, and still, there is no satisfactory treatment. The aim of this study was to evaluate the effects of urotensin-II (U-II) antagonist palosuran in an animal model of scleroderma. We also planned to measure U-II, endothelin-1 (ET-1), and transforming growth factor-β1 (TGF-β1) levels, as well as the association of these levels with dermal thickness. Twenty-four male mice were included in this study and they were divided into three groups--group 1: control group, group 2: fibrosis group, and group 3: fibrosis + palosuran treatment group. Fibrosis + palosuran treatment in group 3 reduced ET-1, U-II, and TGF-β1 levels. In total, the diminished values were statistically significant in the ET-1 and TGF-β1 levels (p < 0.05). Dermal thickness was higher in the fibrosis group, when compared with the other groups. There was no significant relationship between dermal thickness and ET-1, U-II, or TGF-β1 levels (p > 0.05). It is believed that U-II is an important mediator in SSc, and its antagonism with palosuran could be a new treatment choice in SSc.
authors.affiliation: Department of Physiology, Gaziantep University School of Medicine, Gaziantep, 27310, Turkey. drtuncer2003@yahoo.com
authors.forename: Tuncer
authors.initials: T
authors.lastname: Demir
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Turkbeyler
authors.forename: Davut Sinan
authors.initials: DS
authors.lastname: Kaplan
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Pehlivan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Orkmez
authors.forename: Ediz
authors.initials: E
authors.lastname: Tutar
authors.forename: Seyithan
authors.initials: S
authors.lastname: Taysi
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Kisacik
authors.forename: Ahmet Mesut
authors.initials: AM
authors.lastname: Onat
authors.forename: Cahit
authors.initials: C
authors.lastname: Bagcı
mesh_terms: D000818:Animals; D001761:Bleomycin; D019332:Endothelin-1 / Q000032:analysis; D005109:Extracellular Matrix / Q000378:metabolism; D005355:Fibrosis / Q000188:drug therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011804:Quinolines / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D053773:Transforming Growth Factor beta1 / Q000032:analysis; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014579:Urotensins / Q000037:antagonists & inhibitors*
chemical_list: D019332:Endothelin-1; D011804:Quinolines; D053773:Transforming Growth Factor beta1; D014579:Urotensins; D001761:Bleomycin; D014508:Urea; C029677:urotensin II; C493249:1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea